Advanced Therapies: Biotechnology to Transform the Future of Health
At Farmalider, we have turned research, development, and pharmaceutical manufacturing into the driving force behind our growth and our commitment to health.
Today, more than ever, we look to the future with determination, investing in biotechnology, disruptive research, and new scientific challenges that enable us to lead the transition toward a more advanced, effective, and accessible medicine.
We explore innovative approaches in clinical areas with limited therapeutic options and develop advanced therapy projects, offering scalable manufacturing infrastructure aligned with current European regulatory standards
Innovation with Purpose: Advanced Therapy Development
Through a flexible, scalable infrastructure fully aligned with current European regulations, we develop projects in the field of Advanced Therapy Medicinal Products (ATMPs), focusing on:
Regenerative medicine
Immunotherapy
Cell therapies with transformative potential
Our approach integrates the entire value chain—from preclinical research to GMP manufacturing—driving science that translates into real well-being for people.
We walk this path alongside our two partner companies:
Ideeea Therapeutics
An innovative biotechnology startup specialized in the development of ATMPs focused on regenerative medicine and immunotherapy.
Through an open innovation model, Ideeea closely collaborates with leading hospitals and research centers to integrate the entire process—from the exploratory phase to GMP production under European standards.
ThyTech
A clinical biotechnology company focused on developing immunological cell therapies based on thymic-derived, primarily allogeneic, regulatory T lymphocytes (Treg).
ThyTech researches new ways to modulate immune responses in autoimmune and inflammatory diseases, paving the way for more effective and long-lasting solutions.
Transformative Vision in Pharmaceutical Biotechnology
At Farmalider, we embrace biotechnology as a driver of change in the healthcare sector. Our strategic investment in advanced therapies reflects a strong commitment to science, responsible innovation, and the development of medicines that address real medical challenges.
Thanks to our capabilities in clinical development, regulatory affairs, GMP manufacturing, and scientific-hospital partnerships, we are ready to scale the treatments of the future—from the laboratory to the patient.